The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin-proteasome system and α-synuclein
Open accessAbstract
In animals, sporadic injections of the mitochondrial toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively damage dopaminergic neurons but do not fully reproduce the features of human Parkinson's disease. We have now developed a mouse Parkinson's disease model that is based on continuous MPTP administration with an osmotic minipump and mimics many features of the human disease. Although both sporadic and continuous MPTP administration led to severe striatal dopamine depletion and nigral cell loss, we find that only continuous administration of MPTP produced progressive behavioral changes and triggered formation of nigral inclusions immunoreactive for ubiquitin and α-synuclein. Moreover, only continuous MPTP infusions caused long-lasting activation of glucose uptake and inhibition of the ubiquitin-proteasome system. In mice lacking α-synuclein, continuous MPTP delivery still induced metabolic activation, but induction of behavioral symptoms and neuronal cell death were almost completely alleviated. Furthermore, the inhibition of the ubiquitinproteasome system and the production of inclusion bodies were reduced. These data suggest that continuous low-level exposure of mice to MPTP causes a Parkinson-like syndrome in an α-synuclein-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263
Nicklas, W. J., Vyas, I., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,262
Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration
Schmued, L. C., & Hopkins, K. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02513-0 · Cited by 1,218
Heikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
Dopaminergic Neurotoxicity of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine in Mice
Heikkila, R. E., Hess, A., & Duvoisin, R. C. (1984) · Science · doi:10.1126/science.6610213 · Cited by 1,009
The Ubiquitin Proteasome System in Neurodegenerative Diseases
Ciechanover, A., & Brundin, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00606-8 · Cited by 982
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W., Kholodilov, N., Vila, M., Trillat, A.-C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 581
Cited by
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455
Protocol for the MPTP mouse model of Parkinson's disease
Jackson-Lewis, V., & Przedborski, S. (2007) · Nature Protocols · doi:10.1038/nprot.2006.342 · Cited by 1,111
Mitochondrial fragmentation in neurodegeneration.
Knott, A. B., Perkins, G., Schwarzenbacher, R., & Bossy-Wetzel, E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2417 · Cited by 1,002
Mitochondrial Glutathione, a Key Survival Antioxidant
Marí, M., Morales, A., Colell, A., García-Ruiz, C., & Fernández-Checa, J. C. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2695 · Cited by 980
α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration
Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O. M., & Südhof, T. C. (2005) · Cell · doi:10.1016/j.cell.2005.09.028 · Cited by 966
Self-citationMitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
Mitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S. R., & Chesselet, M.-F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 913
Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.04.004 · Cited by 762
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Parkinson's disease: Mechanisms, translational models and management strategies
Raza, C., Anjum, R., & Shakeel, N. U. A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.057 · Cited by 603
Ageing, age-related diseases and oxidative stress: What to do next?
Luo, J., Mills, K., le Cessie, S., Noordam, R., & van Heemst, D. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100982 · Cited by 581
“…(MPTP), and rotenone, both of which are mitochondrial complex I inhibitors, have been demonstrated to result in clinical PD phenotype by producing pathological degeneration of dopaminergic neurons of the substantia nigra (Betarbet et al., 2000; Fornai et al., 2005).”
BackgroundMPTP Mouse Models of Parkinson's Disease: An Update
Meredith, G. E., & Rademacher, D. J. (2011) · Journal of Parkinson’s Disease · doi:10.3233/jpd-2011-11023 · Cited by 514
Neurotoxin-based models of Parkinson's disease
Bové, J., & Perier, C. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.057 · Cited by 506
Classic and New Animal Models of Parkinson's Disease
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/845618 · Cited by 505
A Guide to Neurotoxic Animal Models of Parkinson's Disease
Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483
Shults, C. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509567103 · Cited by 476
Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschmar, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1114-9 · Cited by 457
Chinta, S. J., Mallajosyula, J. K., Rane, A., & Andersen, J. K. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.061 · Cited by 449
Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling
Wu, Y., Chen, M., & Jiang, J. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.07.003 · Cited by 385
Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378
Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, B. T., McLean, P. J., & Unni, V. K. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1560-11.2011 · Cited by 377
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S., Youdim, M. B. H., & Riederer, P. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 352
PINK1 protein in normal human brain and Parkinson's disease
Gandhi, S. (2006) · Brain · doi:10.1093/brain/awl114 · Cited by 342
Betarbet, R., Canet-Aviles, R. M., Sherer, T. B., Mastroberardino, P. G., McLendon, C., Kim, J.-H., Lund, S., Na, H.-M., Taylor, G., Bence, N. F., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.003 · Cited by 342
The 6-hydroxydopamine model: News from the past
Blandini, F., Armentero, M.-T., & Martignoni, E. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.015 · Cited by 311
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease
Dodson, M. W., & Guo, M. (2007) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2007.04.010 · Cited by 278
Lau, Y.-S., Patki, G., Das-Panja, K., Le, W.-D., & Ahmad, S. O. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07626.x · Cited by 275
“Infusion of the mitochondrial complex I inhibitor rotenone or MPTP produces oxidative damage resulting in selective loss of SN DA neurons and build-up of cytoplasmic a-synuclein-immunoreactive inclusions (Betarbet et al., 2000; Fornai et al., 2005).”
BackgroundToxin Models of Mitochondrial Dysfunction in Parkinson's Disease
Martinez, T. N., & Greenamyre, J. T. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4033 · Cited by 266
Filomeni, G., Graziani, I., De Zio, D., Dini, L., Centonze, D., Rotilio, G., & Ciriolo, M. R. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.021 · Cited by 262
Initiation and propagation of α-synuclein aggregation in the nervous system
Hijaz, B. A., & Volpicelli-Daley, L. A. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00368-6 · Cited by 262
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Protein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis
Banerjee, R., Starkov, A. A., Beal, M. F., & Thomas, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.007 · Cited by 253
Impairing the Mitochondrial Fission and Fusion Balance: A New Mechanism of Neurodegeneration
Knott, A. B., & Bossy‐Wetzel, E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.030 · Cited by 252
Molecular pathogenesis of Parkinson's disease
Gandhi, S., & Wood, N. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi308 · Cited by 251
Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Moreover, an impairment of the UPS activity in the nigrostriatal system parallels mitochondrial dysfunction in PD patients (Ambrosi et al.”
BackgroundResultInfluentialImplications of time-series gene expression profiles of replicative senescence.
Kim, Y., Byun, H., Jee, B. A., Cho, H., Seo, Y., Kim, Y., Park, M. H., Chung, H., Woo, H. G., & Yoon, G. (2013) · Aging Cell · doi:10.1111/acel.12087 · Cited by 106
Targeting the Progression of Parkinsons Disease
George, J., Mok, S., Moses, D., Wilkins, S., Bush, A., Cherny, R., & Finkelstein, D. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602814 · Cited by 77
Joers, V., Masilamoni, G., Kempf, D., Weiss, A. R., Rotterman, T. M., Murray, B., Yalcin-Cakmakli, G., Voll, R. J., Goodman, M. M., Howell, L., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105027 · Cited by 56
Peralta, S., Torraco, A., Wenz, T., Garcia, S., Diaz, F., & Moraes, C. T. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt526 · Cited by 42
Masilamoni, G. J., Groover, O., & Smith, Y. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.025 · Cited by 37
“…indicating that chronic low dose regimen of MPTP administration mimic much more closely the slow and progressive degeneration and dopaminergic and non-dopaminergic cell groups described in idiopathic PD (Forno et al., 1986; Hantraye et al., 1993; Fornai et al., 2005; Masilamoni et al., 2010).”
BackgroundResultNavarro-Yepes, J., Anandhan, A., Bradley, E., Bohovych, I., Yarabe, B., de Jong, A., Ovaa, H., Zhou, Y., Khalimonchuk, O., Quintanilla-Vega, B., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9414-9 · Cited by 37
Landeck, N., Strathearn, K. E., Ysselstein, D., Buck, K., Dutta, S., Banerjee, S., Lv, Z., Hulleman, J. D., Hindupur, J., Lin, L.-K., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00380-w · Cited by 19
Metadata
- Authors
- Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G., Pellegrini, A., Nicoletti, F., Ruggieri, S., Paparelli, A., & Südhof, T. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-02-16
- Volume
- 102
- Issue
- 9
- Pages
- 3413-3418
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2128672762
- Cited by
- 526
- References
- 38
- FWCI
- 29.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.